{
    "nctId": "NCT00496860",
    "briefTitle": "Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies",
    "officialTitle": "Phase I Study of ALT-801 in Patients With Progressive Metastatic Malignancies",
    "overallStatus": "COMPLETED",
    "conditions": "Progressive Metastatic Malignancies",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 26,
    "primaryOutcomeMeasure": "The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies",
    "eligibilityCriteria": "ENTRY CRITERIA:\n\nDISEASE CHARACTERISTICS:\n\n* Locally advanced or metastatic malignancies\n* Histologically or cytologically confirmed\n* Evaluable\n* Surgically and medically incurable\n* Not responding to standard therapy or no other standard therapy exists\n* Human leukocyte antigen (HLA)-A2.1/p53 positive\n\nPRIOR/CONCURRENT THERAPY:\n\n* No prior Proleukin therapy within one year\n* No concurrent radiotherapy, chemotherapy, or other immunotherapy\n* More than 4 weeks since prior major radiotherapy\n* More than 4 weeks since prior cytotoxic therapy\n* More than 6 weeks since prior nitrosoureas therapy\n* More than 8 weeks since prior monoclonal antibody therapy\n\nPATIENT CHARACTERISTICS:\n\nLife expectancy\n\n* \\> 3 months\n\nPerformance status\n\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1\n\nBone marrow reserve\n\n* Absolute neutrophil count (AGC/ANC) \u2265 1,500/microliters (uL)\n* Platelets \u2265100,000/uL\n* Hemoglobin \u2265 10g/dL\n\nRenal function\n\n* Serum creatinine \u2264 1.5 X Upper limit of normal (ULN)\n\nHepatic function\n\n* Total bilirubin \u2264 1.5 X ULN\n* Aspartate Aminotransferase (AST) \u2264 2.5 X ULN\n* Alkaline phosphatase \u2264 2.5 X ULN\n* Prothrombin time (PT) or international normalized ratio (INR) \u2264 1.5 X ULN\n* Activated partial thromboplastin time (aPTT) \u2264 1.5 X ULN\n\nCardiovascular\n\n* May be safely tapered off anti-hypertensives if currently on anti-hypertensives\n* New York Heart Association classification I or II\n* No congestive heart failure \\<6 months\n* No unstable angina pectoris \\<6 months\n* No myocardial infarction \\<6 months\n* No history of ventricular arrhythmias\n* Normal cardiac stress test required if any of the following is present:\n\n  * Over age 50\n  * History of abnormal EKG\n  * Symptoms of cardiac ischemia or arrhythmia\n\nPulmonary\n\n* Normal pulmonary function test (FEV1 \u2265 75% of predicted value) if any of the following is present:\n\n  * Prolonged history of cigarette smoking\n  * Symptoms of respiratory dysfunction\n\nOther\n\n* No known autoimmune disease\n* No known HIV positive\n* No psychiatric illness/social situations that would limit study compliance\n* No history or evidence of central nervous system (CNS) disease\n* No active systemic infection requiring parental antibiotic therapy\n* No systemic steroid therapy required\n* No prior organ allograft\n* Not receiving other investigational agents\n* Not receiving chronic medication for asthma\n* Not pregnant or nursing\n* Fertile patients must use effective contraception",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}